Gilead Sciences (GILD) Tops Q3 EPS by 32c; offers guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $123.76 -1.35%
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.47, $0.32 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.45 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $8.05-$8.25, versus the consensus of $8.05. Gilead Sciences sees FY2025 Product revenue of $28.4-28.7 billion, versus the consensus of $28.836 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
- Huntington Ingalls wins $418M Navy contract
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
